Even before the pandemic hit, the hair restoration industry was booming (it’s projectedย to reach over $12 billion in 2026). Add in theย stress-included hair lossย that weโve seen during the COVID-19 pandemic, and suddenly all eyes are on the scalp.
It may be surprising that, in a marketย set to see significant growthย in the next few years, we’re arguably lacking in great solutions to the problem โ particularly for women, who aren’t always candidates for all the treatments currently available to men. In fact, of the two FDA-approved drugs on the hair rejuvenation market, minoxidil and finasteride (aka Rogaine and Propecia, respectively), only Rogaine is also approved for women. But with advances in technology and other innovations on the horizon, that all may change in the next few years.